A Phase 2 Study of LY2090314 in Participants With Acute Leukemia.
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2014
At a glance
- Drugs LY 2090314 (Primary)
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Eli Lilly
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Feb 2012 Planned number of patients changed from 26 to 38 as reported by M.D. Anderson Cancer Center.
- 21 Feb 2012 New source identified and integrated (2011-0838; M.D. Anderson Cancer Center).